FDA signs off on GE Healthcare's Alzheimer's imaging agent

GE Healthcare ($GE) has gained FDA approval for an imaging agent designed to help evaluate patients for Alzheimer's disease or dementia. Regulators announced the approval, which designates flutemetamol--now called Vizamyl--as a "radioactive diagnostic drug" for use in PET imaging of the brain in adults being scrutinized for either condition. Patents are injected with the agent before PET scans designed to detect beta amyloid deposits in the brain, which are widely believed to be red flags for Alzheimer's development. Vizamyl attaches to the beta amyloid. Last year, GE licensed the agent to Merck ($MRK) for use on select trial participants for MK-8931, Merck's hoped-for Alzheimer's blockbuster drug. FDA notice | GE release | FierceDiagnostics' take

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.